Alcohol Dependence and Its Relationship With Insomnia and Other Sleep Disorders

Subhajit Chakravorty, Ninad S. Chaudhary, and Kirk J. Brower

Sleep-related complaints are widely prevalent in those with alcohol dependence (AD). AD is associated not only with insomnia, but also with multiple sleep-related disorders as a growing body of literature has demonstrated. This article will review the various aspects of insomnia associated with AD. In addition, the association of AD with other sleep-related disorders will be briefly reviewed. The association of AD with insomnia is bidirectional in nature. The etiopathogenesis of insomnia has demonstrated multiple associations and is an active focus of research. Treatment with cognitive behavioral therapy for insomnia is showing promise as an optimal intervention. In addition, AD may be associated with circadian abnormalities, short sleep duration, obstructive sleep apnea, and sleep-related movement disorder. The burgeoning knowledge on insomnia associated with moderate-to-severe alcohol use disorder has expanded our understanding of its underlying neurobiology, clinical features, and treatment options.

Key Words: Alcohol, Alcoholism, Sleep, Sleep Initiation and Maintenance Disorders.

M O D E R A T E - T O - S E V E R E alcohol use disorder (or alcohol dependence [AD]) has been associated with a range of sleep-related disturbances. These disturbances may have direct ramifications on the underlying AD and on the overall health and social well-being of the individual. The last comprehensive review on this topic was published in March 2005 (Stein and Friedmann, 2005).

Over this past decade, knowledge in the field of sleep-related disorders has grown considerably with the evolution of sleep medicine and behavioral sleep medicine as independent subspecialties, along with improved comprehension of sleep disorders and their treatments. Another ramifications of this growing body of knowledge is the revision in the diagnostic criteria for sleep disorders. These updated criteria are seen in the third edition of the International Classification of Sleep Disorders (ICSD-3) (AASM, 2014) and the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) (APA, 2013). In this review, we will adhere to the ICSD-3 classification for sleep disorders.

This exponential growth in information has also started to change the way we conceptualize and treat insomnia and other sleep-related disturbances associated with AD. It is with these facts in mind that we decided to review this growing body of knowledge. The primary aim of this article was to review the literature related to insomnia associated with AD with a focus on its clinical manifestations, etiology, pathogenesis, and associated treatment interventions. The secondary aim was to briefly review literature on other sleep-related disorders associated with AD that sometimes present as insomnia.

MATERIALS AND METHODS

The selection of manuscripts for this review was conducted in 4 steps. First, search terms were formulated to cover the effects of alcohol intoxication on sleep and the association of AD with various sleep-related disorders including insomnia, circadian rhythm sleep disorders, breathing-related sleep disorders, sleep-related movement disorders, and parasomnias. Second, appropriate search terms were applied to 4 different databases, namely PubMed, MEDLINE, Embase, and Google Scholar to maximize retrieval of abstracts in the United States, European, and other international databases. These searches were limited to human subjects, English language, and studies directly evaluating the relationships of alcohol use/disorder and sleep complaints/disorders (see Supplemental file for search terminology). Wherever multiple studies were seen on the same topic, the largest studies and/or the most rigorous studies were evaluated. The dates of the literature were January 1, 1967 to December 31, 2015. Third, the references of the selected manuscripts were reviewed for additional manuscripts in our areas of interest. As a final step, we also reviewed the last 2 literature reviews on this subject along with their references to extract additional manuscripts (Brower, 2001; Stein and Friedmann, 2005). A total of 135 manuscripts were reviewed for this article. See Fig. 1 for details. The primary author reviewed the manuscripts and checked the tables for
accuracy and consistency. Alcohol’s association with hypersomnia disorders was excluded from this review as it was considered beyond the scope of this current article.

RESULTS

In healthy subjects, the time lag after lying in bed with the intention to sleep and actual sleep is referred to as sleep onset latency (SOL). Once an individual falls asleep, he or she alternates between 2 states of sleep—nonrapid eye movement sleep (NREM) and rapid eye movement sleep (REM). NREM is characterized by a succession of stages traditionally called 1 to 4 (Rechtschaffen and Kales, 1968). Slow-wave sleep (SWS) or deep sleep corresponds to stages 3 and 4 combined. These stages correspond to a progressive increase in the depth of NREM sleep with an associated decrease in frequency and an increase in amplitude of the brain waves, as measured by sleep electroencephalography (EEG). Nocturnal monitoring of sleep EEG, breathing, and movements in the sleep laboratory is known as polysomnography (PSG). About 90 minutes after the onset of NREM sleep, a person enters into REM sleep characterized by a decrease in the EEG amplitude (height of the waves), mixed-frequency waves, rapid eye movements, and loss of muscle tone (as reflected in a low chin electromyography tone (Iber et al., 2007; Siegel, 2017). Saw-tooth waves may also appear as a superimposed rhythm with a frequency of 2 to 3 Hz and a triangular shape with the appearance of teeth on a saw (Berger et al., 1962; Pearl et al., 2002). The timing and duration of each state and stage of sleep throughout the night is called sleep architecture. For further information on sleep-related variables, see Table 1.

In addition to the electrophysiologic mechanisms of sleep, Borbely (1982) postulated a 2-process model of sleep regulation. In brief, this model posits that sleep is a function of 2 independent mechanisms, namely homeostatic sleep drive and circadian rhythmicity. The homeostatic mechanism is responsible for a build-up of the sleep drive with continued wakefulness through the day, whereas the circadian mechanism is responsible for maintenance of wakefulness and is influenced by zeitgebers such as ambient light and meal times. One or both mechanisms may be weakened or abnormal in insomnia. A mismatch between the normally synergistic circadian and homeostatic mechanisms may also lead to circadian rhythm sleep disorders.

Alcohol and Its Effect on Sleep Continuity in Healthy Subjects

The alcohol level in blood is determined by gender, weight, number of drinks consumed over a unit of time, and rate of metabolism. It is generally metabolized at a rate of 0.01 to 0.02 g% per hour (Arnedt et al., 2011b). When alcohol is consumed before bedtime, its effects on sleep architecture also differ based on the ascending or peak concentrations during the first 3 to 4 hours of the night (first half of the night) as compared to the descending phase of blood alcohol levels during the next 3 to 4 hours of sleep (second half of the night).

The effect of moderate and heavy alcohol intake on sleep in healthy adults has been investigated across multiple studies although most of these studies were limited with their small sample sizes. With moderate doses of alcohol (<1 g/kg), the only consistent PSG sleep finding has been decreased REM sleep duration (Miyata et al., 2004; Roehrs et al., 1991; Williams et al., 1983). Analysis of sleep across the first half of the night did not demonstrate any consistent changes in PSG sleep. In the second half of the night, the consistent finding was decreased REM sleep duration (Miyata et al., 2004; Rundell et al., 1972). Recently, Arnedt and colleagues (2011b) conducted one of the largest studies of sleep in heavy drinking healthy adults. They demonstrated that alcohol at a dose of >1 g/kg, as compared with placebo, decreased SOL and sleep efficiency (SE; percentage of time in bed spent sleeping) and increased wake after sleep onset time (WASO). Alcohol’s effects on sleep architecture included an increase in REM latency, increase in SWS (SWS%) and an increase in stage 2 sleep, along with a decrease in REM%. During the first half of the night, alcohol, as compared to placebo,
increased total sleep time (TST) and SE and decreased the number and duration of awakenings. However, during the second half of the night, TST and SE were decreased, with an increased number and duration of awakenings (Arnedt et al., 2011b). Similar findings of sleep disruption have been demonstrated in late adolescence (Chan et al., 2013), although their EEG power spectra analysis after alcohol consumption demonstrated simultaneous increases in frontal delta and alpha powers during the earlier part of sleep, which may lead to sleep disturbance (Chan et al., 2015). Last, after consumption of alcohol earlier in the evening and despite an undetectable breath alcohol level, subjects’ sleep was seen to be superficial (subjectively) with high-frequency EEG activity (objectively), thus demonstrating an increased arousal within their sleep (Landolt et al., 1996).

In summary, moderate doses of alcohol may decrease the amount of REM sleep through the night. In doses mimicking heavy drinking, alcohol may initially improve sleep continuity during the first half of the night; however, in the second half of the night, it may lead to fragmented sleep (more awakenings). Furthermore, alcohol may continue to disturb sleep even after the breath alcohol concentration is undetectable.

**Insomnia**

**Introduction.** Insomnia is the most investigated sleep disorder, although some of these studies have evaluated insomnia symptoms in lieu of it as a disorder. Insomnia disorder as defined by the ICSD-3 requires the presence of ≥1 of the following complaints: difficulty initiating sleep, difficulty maintaining sleep, or waking up earlier than desired. These symptoms are associated with ≥1 of the following impairments: fatigue or malaise, attention or memory problems, impairment of psychosocial functioning, mood disturbance, daytime sleepiness, behavioral problems, reduced motivation or energy, proneness for errors, and concern or dissatisfaction with sleep. These complaints must occur despite adequate opportunity and circumstances for sleep and are present for most nights of the week for ≥3 months (AASM, 2014). The criteria for insomnia disorder in DSM-5 are nearly identical.

**Alcohol Dependence.** Insomnia or sleep disturbance is widely prevalent in AD. The prevalence estimates range from 36 to 91% (Baekeland et al., 1974; Brower et al., 2001; Chaudhary et al., 2015; Cohn et al., 2003; Mello and Mendelson, 1970). AD may be categorized into different stages based on the temporal relationship with exposure to alcohol. Insomnia has been associated with all of these stages and is briefly reviewed below, taking into account different populations wherever applicable.

**During Active Alcohol Use:**

1. Treatment-seeking AD subjects—There is a limited body of literature on insomnia associated with active alcohol use in AD. These studies may be categorized based on their use of subjective or objective measures:

   a. **Subjective measures.** The prevalence rate of insomnia was 74% in a recent study that used the Insomnia Severity Index (Chaudhary et al., 2015). In 1 study,
30% of the subjects were actively drinking during treatment. They complained of increased sleep latency and fragmentation of their sleep (Skoloda et al., 1979). In another investigation, staff assessments in an inpatient rehabilitation unit demonstrated that those who continued to drink had sleep fragmentation and a reduction of their TST (Mello and Mendelson, 1970).

b. Objective measures. PSG sleep studies in subjects with AD and alcohol consumption also found increased SOL, decreased TST, and sleep architectural changes including decreased REM sleep duration and both increased REM sleep latency and SWS (Gross and Hastey, 1975; Gross et al., 1973). These findings contrast with another study where increased TST with alcohol consumption was seen (Allen et al., 1980).

2. Nontreatment-seeking problem drinkers—In a recent study of nontreatment-seeking problem drinkers in the community (N = 295), Hartwell and colleagues (2015) used the Pittsburgh Sleep Quality Index (PSQI) to demonstrate a 76% prevalence rate of sleep disturbance. They defined sleep disturbance using a PSQI total score > 5. In addition, they also used a 3-factor scoring model to evaluate insomnia; these factors consisted of SE, perceived sleep quality, and daily disturbances. In this study, sleep disturbance was positively associated with alcohol problem severity.

3. Veterans—In a chart review of Veterans with AD (N = 84), insomnia symptoms included increased SOL (72 ± 67 minutes) and WASO time (82 ± 13 minutes), and poor sleep quality in 63% of patients. These insomnia symptoms were prevalent for 75 ± 123 months (Chakravorty et al., 2013). One of the strongest predictors of insomnia symptoms was the presence of a psychiatric disorder (OR = 20.8).

In summary, the preponderance of studies reports subjective and objective increase in SOL and sleep fragmentation with consequently decreased TST in actively drinking subjects with AD.

During Acute Withdrawal: The withdrawal phase after acute cessation of sustained alcohol use lasts about 1 to 2 weeks with a prevalence rate of sleep complaints that is variable. Steinig and colleagues (2011) demonstrated that 92% of inpatients with AD acutely withdrawing from alcohol had sleep disturbance. In a study of Brazilian subjects undergoing inpatient alcohol detoxification (N = 58), subjective sleep disturbance was prevalent in all women (100%, 13/13) and most men, 88.9% (40 of 45) (Escobar-Cordoba et al., 2009). In another investigation involving subjects in a residential treatment program, the symptom of “inability to sleep” differed in prevalence across race and ethnicity. In this treatment-seeking sample of male patients, the prevalence was lowest in Blacks (54%), highest in Whites (82%), and with an intermediate prevalence of 65% in Mexican Americans males (Caetano et al., 1998).

These insomnia symptoms may improve with time as the detoxification progresses. Bokstrom and Balldin (1992) demonstrated a decrease in the mean ± SD insomnia scores from 1.3 ± 1.1 (N = 48) to 0.8 ± 1.0 (N = 13), p = 0.01 for days 0 versus 7 after last alcohol use during inpatient detoxification. In the general population, the prevalence rate of insomnia as a withdrawal symptom was 32% among alcohol-dependent individuals (Brower and Perron, 2010).

In patients with delirium tremens (DTs), a higher percentage of stage 1 sleep with REM (stage 1 period with low voltage EEG with REM) was demonstrated (Greenberg and Pearlman, 1967). In this study, 1 of the subjects had nightmares of hallucinatory intensity during alcohol withdrawal and demonstrated 100% stage 1-REM sleep. As DTs ended, recovery sleep set in as a response to sleep deprivation in most of these patients. However, a subset of patients may have fragmented sleep and disturbances of consciousness that predict a guarded prognosis for future episodes of DTs (Kotorii et al., 1982; Nakazawa et al., 1981).

During Recovery from Alcohol Use: Early Recovery (2 to 8 weeks after detoxification)—Some studies have reported a mild withdrawal syndrome persisting after the cessation of an acute withdrawal phase. This condition may be secondary to a hyperexcitable state of the central nervous system (Begleiter and Porjesz, 1979) and has been called protracted abstinence, protracted withdrawal phase, or late withdrawal symptoms (Heilig et al., 2010). Its main features include mood disturbance, alcohol craving, and sleep-related disturbances, and they may persist for about 5 weeks (Alling et al., 1982).

Sleep problems are common during this phase and may be prevalent in about 65% of individuals during this phase (Brower et al., 2001; Kolla et al., 2014). Subjective complaints in those with insomnia as compared to those without include longer SOL, increased WASO, and lower SE (Brower et al., 2001; Conroy et al., 2006). PSG sleep findings during the first 8 weeks of abstinence include increased SOL and stage 1 sleep and decreased TST and SWS% (Brower et al., 2001; Gillin et al., 1990a, b; Le Bon et al., 1997; Moeller et al., 1993). REM sleep findings have been inconsistent during this phase with some studies reporting a decreased REM sleep latency and increased REM% (Gillin et al., 1990a, b; Williams and Rundell, 1981), whereas other studies did not (Gillin et al., 1990b; Le Bon et al., 1997). It is to be noted that individuals in early recovery may overestimate their subjective SOL but underestimate their WASO, as compared to their PSG estimated indices (Conroy et al., 2006).

Those who relapse to alcohol use during treatment may have more disturbed sleep, as compared to abstainers (Brower, 2003; Conroy et al., 2006; Currie et al., 2004; Smith et al., 2014). In contrast, 2 studies have failed to demonstrate such a relationship with subjective insomnia (Feige et al., 2007; Jakubczyk et al., 2013) as measured by the Athens Insomnia Scale and PSQI, respectively; however, the latter study demonstrated an association of relapse with increased sleep EEG β2 spectral power. It is possible that the use of
alcohol as a sleep aid rather than the sleep disturbance itself is associated with relapse, as demonstrated in a recent study (Kolla et al., 2015).

Sustained Recovery (≥3 months beyond detoxification phase)—Subjective and objective sleep-related disturbances persist for up to 3 years into sobriety as demonstrated by cross-sectional and longitudinal studies. Subjective complaints of insomnia may persist up to 2 years into sobriety (Cohn et al., 2003; Kissin, 1979; Wellman, 1954). Longitudinal studies evaluating PSG sleep have demonstrated the presence of increased SOL and sleep fragmentation, a decreased TST, and abnormalities in SWS and REM sleep stages. Although increased SOL reached normal levels by 5 to 9 months into recovery, sleep fragmentation persisted for 21 months, and consequently, TST was seen to normalize in ≤2 years (Adamson and Burdick, 1973; Drummond et al., 1998; Williams and Rundell, 1981). SWS is decreased early in recovery and gradually normalizes over time and around 2 years of sobriety (Drummond et al., 1998; Imatoh et al., 1986; Williams and Rundell, 1981).

There is some inconsistency in the literature relating to REM sleep abnormalities during sustained recovery. In 1 study, REM sleep architecture demonstrated a reversal during early recovery, with the first REM sleep episode of the night being the longest, despite a lack of depressive disorder in these subjects (Imatoh et al., 1986). The REM sleep architecture normalized over time with continued recovery (Imatoh et al., 1986). This phenomenon may suggest a normalization of the acrophase of REM sleep with sobriety and may also account for increased REM% during early recovery. In a frequently cited study, decreased REM sleep latency and increased REM% was seen at 27 months into recovery (Drummond et al., 1998). These findings contrast with lack of REM sleep abnormalities reported in 2 other studies, as compared to healthy control subjects (Schiavi et al., 1995; Williams and Rundell, 1981). Discrepancies in REM sleep may reflect sample differences, duration of sobriety (where the REM sleep may have normalized over time) (Williams and Rundell, 1981), or an interaction between REM sleep architecture and a circadian disruption (Imatoh et al., 1986).

Other Information on Sleep in Recovering Alcoholics: Sleep Hygiene—Poor sleep hygiene may perpetuate insomnia. Napping was common during recovery in 1 study resulting in longer WASO times, decreased TST, and lower SE (Currie et al., 2003).

Dreams and Nightmares—Dreams and nightmares may lead to insomnia and sleep fragmentation. In a study of subjects with AD during acute alcohol detoxification, in addition to a poor sleep quality, only 21% had dreams about alcohol. Dream content was described as “strange, foreign” and as if “from another world.” As abstinence progressed, dreams became less strange and aggressive (Steinig et al., 2011). An unreplicated finding is that drinking-related dreams were positively associated with length of abstinence (Choi, 1973).

Epidemiology of Insomnia in Alcohol Dependence: There is a growing body of literature demonstrating a bidirectional relationship of insomnia with alcohol consumption and alcohol misuse.

Sleep problems and future alcohol use. Retrospectively, subjects with AD reported the presence of insomnia prior to the onset of AD (Currie et al., 2003). Sleep disturbance has been shown to predict subsequent alcohol consumption in adolescents and adults (Breslau et al., 1996; Ford and Kamerow, 1989; Weissman et al., 1997; Wong et al., 2004, 2010, 2015). This association may be secondary to subjects self-medicating their insomnia with alcohol (Ancoli-Israel and Roth, 1999; Johnson et al., 1998; Kaneita et al., 2007).

Does AD lead to Insomnia? In a longitudinal Swedish study (N = 2,602), having AD (CAGE questionnaire total score of ≥2) was associated with subsequent insomnia symptoms (OR = 1.75, 95% CI: 1.2 to 2.5) (Janson et al., 2001). Similarly, respondents with chronic AD (N = 248) during longitudinal follow-up were more likely to report insomnia symptoms as compared to those who had remitted (N = 211) during the follow-up period (OR = 2.6, 95% CI: 1.1 to 6.0) (Crum et al., 2004).

What are the ramifications of insomnia in AD? Prior cross-sectional and longitudinal studies have demonstrated the following associations with AD: (i) relapse to drinking (Brower, 2003; Conroy et al., 2006; Currie et al., 2003); (ii) higher psychosocial problems related to the drinking, including recent employment problems, conflicts with others in their environment and impulse control (Chaudhary et al., 2013, 2015; Zhabenko et al., 2012); (iii) decreased self-reported quality of life (Cohn et al., 2003; Zhabenko et al., 2012); (iv) recent and lifetime suicidal ideation (Chaudhary et al., 2015; Klimkiewicz et al., 2012); and (v) insufficient sleep duration (John et al., 2005). The recommended range of sleep duration to support optimal health in adults is 7 to 9 hours (Consensus Conference Panel et al., 2015). Sleep duration ≤6 hours a night has been linked to an increased risk for mortality, injuries, cardio-metabolic and psychiatric problems as well as suicide in adults (Consensus Conference Panel et al., 2015).

What are the Risk Factors for Insomnia/Sleep Problems?: Demographic and other covariates—(i) Age—older age was associated with better subjective sleep quality in 2 studies (Chakravorty et al., 2013; Kolla et al., 2014), although it was inversely associated with objective PSG sleep continuity measures (Brower and Hall, 2001; Gillin et al., 1990b); (ii) relatively lower education (Zhabenko et al., 2012); (iii) marital/partner status—those who were single (Chakravorty et al., 2013; Perney et al., 2012); (iv) monetary problems (Zhabenko et al., 2012); (v) severity of alcoholism (Brower et al., 2001; Hartwell et al., 2015; Zhabenko et al., 2012); (vi) frequency of alcohol use (Zhabenko et al., 2012) although 1 study did not replicate this association (Currie et al., 2003); and (vii) a history of sexual or physical abuse (Zhabenko et al., 2012).

Family history of alcoholism—children and adolescents of parents with AD have demonstrated lower delta power in
Biomarkers of insomnia—a few biomarkers that have been evaluated have included the following: (i) Spectral PSG Studies. High-frequency EEG activity in the beta and gamma range is increased in those with primary insomnia (Perlis et al., 2001a,b); (ii) Studies evaluating Autonomic Activity. Increased sympathetic activity with simultaneously decreased activity of the parasympathetic nervous system, especially during the first 4 hours of the night, was seen in those with AD and sleep disturbance (Irwin et al., 2006; de Zambotti et al., 2014). A recent study has demonstrated that autonomic nervous system abnormalities may improve with sustained recovery (de Zambotti et al., 2015); c) Cytokines. Cytokines such as interleukins (IL) and tumor necrosis factor (TNF) are humoral factors associated with sleep regulation (Krueger and Toth, 1994; Krueger et al., 1998). Studies in subjects with AD, as compared to controls, have demonstrated a decreased production of IL-6 in the early part of the night, suppression of the IL-6/IL-10 through the night, and increased nocturnal levels along with greater increases in IL-6 and TNF-α levels with partial sleep deprivation (Irwin and Miller, 2000; Redwine et al., 2003). Etanercept, a TNF-α antagonist medication, has been shown to decrease the amount and % of REM sleep to a comparable level to age-comparable control subjects (Irwin et al., 2009). Thus, studies involving spectral sleep studies and autonomic activity suggest an increased arousal in sleep disturbance.

Genetic Studies. There is an emerging interest in the associations between AD and circadian clock genes. In a Polish sample of individuals with AD (N = 285), PER34/4 homozygotes reported the highest insomnia scores, PER35/5 genotype reported the lowest scores, and the heterozygotes PER34/5 had an intermediate score (Brower et al., 2012).

A Conceptual Model for Insomnia in AD: Sleep and wakefulness are 2 parallel and competing processes. Sleep onset occurs when there are increased homeostatic (sleep-promoting) and decreased circadian (wake-promoting) drives (Borbely, 1982). From a general neurophysiological perspective, the onset and maintenance of sleep involves depolarizations of the thalamocortical neural circuits (Saper et al., 2010). The “sleep-wake switching system” resides within the lateral hypothalamus, the ventrolateral preoptic area, and the median preoptic area. In contrast to generalized sleep activity across the brain, “local” sleep involves activities in certain neurons or neuronal assemblies leading to regional sleep-like neuronal activity patterns. These activities are then propagated to other brain regions via signaling systems. Insomnia results from a mismatch involving persistent activity in wake-promoting structures during NREM sleep, leading to simultaneous sleep and wake activity along with psychophysiological arousal (Buyssse et al., 2011). From a clinical perspective, insomnia occurs in vulnerable patients with predisposing factors, such as having a family history of AD or certain genetic traits. Acute insomnia is triggered in them by stress-promoting events (precipitating factors). This acute insomnia becomes persistent because of perpetuating factors such as reading in bed (Spielman et al., 1987) or drinking alcohol. Figure 2 presents a conceptual model for insomnia in AD during recovery.

Treatments for Insomnia in AD: Despite the prevalence of insomnia in those with AD, it is not aggressively treated (Friedmann et al., 2003). We have summarized the pharmacologic and behavioral treatments for insomnia in AD in Table 2. These studies have been reviewed in more detail elsewhere (Brooks and Wallen, 2014; Brower, 2016; Kolla et al., 2011a). Medication treatments have demonstrated mixed efficacy. Trazodone was demonstrated to increase alcohol use in 1 randomized, placebo-controlled trial (Friedmann et al., 2008), although this finding was not replicated in an observational study (Kolla et al., 2011b). Similarly, Brower and colleagues (2008) did not demonstrate any superiority of gabapentin over placebo, although Mason and colleagues did report an improvement. In their study of nontreatment-seeking patients with AD, Mason and colleagues (2009) demonstrated an improvement in sleep quality for those treated with gabapentin (1,200 mg a day), as compared to placebo, and after 1 week of treatment, with a mean difference of −2.38, p < 0.05 favoring gabapentin. In a follow-up larger study, the authors replicated the finding of an improvement in sleep quality with gabapentin. It is to be noted that in this latter study, some of the subjects in the treatment arms did not meet criteria for sleep disturbance at baseline (Mason et al., 2014). In a randomized, placebo-controlled trial of heavy drinking subjects with AD (N = 224), quetiapine XR at a dose of 400 mg a day improved sleep quality, as compared to placebo (Litten et al., 2012). Behavioral treatments for insomnia have demonstrated consistent efficacy with moderate to large effect sizes, although these studies have small sample sizes and employed modified versions of cognitive behavioral therapy for insomnia (CBT-I), such as CBTI-AD (Brooks and Wallen, 2014).

In summary, insomnia is prevalent across all stages of AD and may have psychosocial, addiction, and psychiatric ramifications. Although some encouraging results have been seen with gabapentin, quetiapine and CBT-I, these findings need to be replicated using adequately powered studies in individuals with insomnia comorbid with AD.

Alcohol Dependence and Insomnia Associated with Other Sleep Disorders

Other primary sleep disorders may occur more commonly with AD and present as insomnia in the clinical setting. These include obstructive sleep apnea (OSA), periodic limb movement disorder (PLMD), and delayed phase sleep disorder. AD has also been linked with PLMD, circadian rhythm abnormalities, and OSA, which are discussed below. There is a lack of evidence that alcohol consumption is a trigger for sleepwalking (Pressman et al., 2007), although it has been
linked epidemiologically to night terrors, which is another parasomnia (Ohayon et al., 1999).

**Alcohol Dependence and Period Limb Movement Disorder**

The patient with PLMD may present with disturbed sleep and resultant impairment of functioning, which are not explained by another sleep/medical/neurologic/psychiatric disorder (AASM, 2014). It is diagnosed with PSG using a criterion of >15 repetitive limb movements per hour of sleep in adults, mostly in the lower extremities. PLMD is associated with restless legs syndrome (Fulda, 2015) and may masquerade as insomnia.

Among those with AD, treatment-seeking subjects have been demonstrated to have a higher Period Limb Movement Index (PLMI) as compared to controls (Brower and Hall, 2001). A longitudinal study involving patients sober for 2 to 3 weeks after withdrawal demonstrated higher baseline PLMI and PLMI with arousals versus healthy controls (Gann et al., 2002). At the 6-month follow-up, subjects with AD who relapsed had significantly higher PLMI and PLMI with arousals than those who did not. Conversely, another study failed to find a difference in PLMI between those with AD in early recovery and controls (Le Bon et al., 1997). Magnesium supplementation had a mixed result on PLMs in an open-label trial of AD patients (Hornyak et al., 2004).

**Alcohol and Circadian Rhythm Sleep-Wake Disorders**

Circadian rhythms are a manifestation of the activity of the primary endogenous pacemaker, the suprachiasmatic nucleus in the hypothalamus, upon which melatonin acts. Dim light melatonin onset is a commonly used marker for evaluating the activity of the circadian pacemaker and for assessing the changes in circadian phase that is delayed or advanced (Pandi-Perumal et al., 2007). The peak of the salivary melatonin curve occurs around 2 AM in middle-aged males (Zhou et al., 2003). This peak may be blunted or delayed in those with AD (Kuhlwein et al., 2003).
## Table 2. Pharmacologic and Behavioral Treatments for Insomnia in Alcohol Dependence

<table>
<thead>
<tr>
<th>Authors</th>
<th>Selected for insomnia</th>
<th>N</th>
<th>RCT</th>
<th>Daily dose, treatment duration</th>
<th>Primary outcome measure</th>
<th>Time since last drink</th>
<th>Effect on insomnia</th>
<th>Effect on drinking</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acamprosate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Staner and colleagues (2006)</td>
<td>No</td>
<td>24</td>
<td>Yes</td>
<td>1,988 mg/d; 23 days</td>
<td>PSG</td>
<td>0</td>
<td>↓</td>
<td>?</td>
</tr>
<tr>
<td>Perney and colleagues (2012)</td>
<td>Yes*</td>
<td>239</td>
<td>Yes</td>
<td>2 to 3 g/d; 6 months</td>
<td>Short Sleep Index</td>
<td>&lt;10 days</td>
<td>↓</td>
<td>? ↓</td>
</tr>
<tr>
<td>Agomelatine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grosshans and colleagues (2014)</td>
<td>Yes</td>
<td>9</td>
<td>No</td>
<td>25 to 50 mg/d; 6 weeks</td>
<td>Sleep Quality</td>
<td>NA</td>
<td>↓</td>
<td>NA</td>
</tr>
<tr>
<td>Chlormethiazole</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gann and colleagues (2004)</td>
<td>No</td>
<td>20</td>
<td>Yes</td>
<td>Taper protocol; 5 days</td>
<td>PSG</td>
<td>0</td>
<td>↑</td>
<td>NA</td>
</tr>
<tr>
<td>Gabapentin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Karam-Hage and Brower (2000)</td>
<td>Yes</td>
<td>15</td>
<td>No</td>
<td>Gabapentin 200 to 1,500 mg; 4 to 6 weeks</td>
<td>SPQ</td>
<td>4 weeks</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>Karam-Hage and Brower (2003)</td>
<td>Yes</td>
<td>50</td>
<td>No</td>
<td>Gabapentin (888 ± 418 mg) or Trazodone (105 ± 57 mg); 4 to 6 weeks</td>
<td>SPQ</td>
<td>≥4 weeks</td>
<td>↓ G &gt; T</td>
<td>↓ (2 subjects in each group)</td>
</tr>
<tr>
<td>Malcolm and colleagues (2007)</td>
<td>No</td>
<td>68</td>
<td>Yes</td>
<td>Gabapentin/oralzepam taper</td>
<td>Insomnia questions</td>
<td>0</td>
<td>↓</td>
<td>(G &gt; L)</td>
</tr>
<tr>
<td>Brower and colleagues (2008)</td>
<td>Yes</td>
<td>21</td>
<td>Yes</td>
<td>1,500 mg; 6 weeks</td>
<td>PSG</td>
<td>≥1 week</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>Quetiapine XR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chakravorty and colleagues (2014)</td>
<td>Yes</td>
<td>20</td>
<td>Yes</td>
<td>400 mg; 8 weeks</td>
<td>PSG</td>
<td>≥1 month</td>
<td>↓</td>
<td>NA</td>
</tr>
<tr>
<td>Ramelteon</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brower and colleagues (2011)</td>
<td>Yes</td>
<td>5</td>
<td>No</td>
<td>8 mg; 4 weeks</td>
<td>ISI</td>
<td>2 to 13 weeks</td>
<td>↓</td>
<td>Lapse to HD (N = 1)</td>
</tr>
<tr>
<td>Trazodone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Le Bon and colleagues (2003)</td>
<td>Yes</td>
<td>18</td>
<td>Yes</td>
<td>150 to 200 mg; 4 weeks</td>
<td>PSG</td>
<td>≥2 weeks</td>
<td>↓</td>
<td>NA</td>
</tr>
<tr>
<td>Friedmann and colleagues (2008)</td>
<td>Yes</td>
<td>173</td>
<td>Yes</td>
<td>50 to 150 mg; 12 weeks</td>
<td>Sleep Quality</td>
<td>Immediate post-detox phase</td>
<td>↓</td>
<td>↑</td>
</tr>
<tr>
<td>Triazolam</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fabre and colleagues (1977)</td>
<td>Yes</td>
<td>12</td>
<td>No</td>
<td>0.5 to 1.0 mg; 28 days</td>
<td>Sleep diary &amp; Q</td>
<td>5 to 15 days</td>
<td>↓</td>
<td>? ↓</td>
</tr>
<tr>
<td>Behavioral PR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Greeff and Conradie (1998)</td>
<td>Yes</td>
<td>22</td>
<td>Yes</td>
<td>2 weeks</td>
<td>Quality of Sleep</td>
<td>≥1 month in RTP</td>
<td>↓</td>
<td>NA</td>
</tr>
<tr>
<td>Currie and colleagues (2004)</td>
<td>Yes</td>
<td>60</td>
<td>Yes</td>
<td>7 weeks</td>
<td>Sleep diary</td>
<td>≥1 month</td>
<td>↑</td>
<td>↓</td>
</tr>
<tr>
<td>Arnedt and colleagues (2007)</td>
<td>Yes</td>
<td>7</td>
<td>No</td>
<td>8 weeks</td>
<td>Sleep diary</td>
<td>27 to 433 days</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>Arnedt and colleagues (2011a)</td>
<td>Yes</td>
<td>17</td>
<td>Yes</td>
<td>8 weeks</td>
<td>Sleep diary</td>
<td>8 to 433 days</td>
<td>↓</td>
<td>?</td>
</tr>
</tbody>
</table>

N, number of subjects in the study; RCT, randomized controlled trial; SPQ, Sleep Problems Questionnaire; PSG, polysomnography; G, gabapentin; T, trazodone; L, lorazepam; ISI, Insomnia Severity Index; RTP, residential treatment program; Q, Questionnaire; HD, heavy drinking; ↑, increased; ↓, decreased; ?, unknown effect; NA, not applicable as not investigated; ∅, no difference; Immediate post-detox phase: evaluated after 3- to 5-day detoxification protocol; PR, progressive relaxation (including muscle relaxation); CBT-I, cognitive behavioral therapy for insomnia.

*This was the secondary aim of this review, which is in itself a secondary analysis of data from a clinical trial.

**Insomnia questions from the CIWA (Clinical Institute Withdrawal Assessment Scale for Alcohol—Revised) and BDI (Beck Depression Inventory) questionnaires.

Selection criteria = studies with sleep as the primary outcome.
Consequently, AD subjects may be more likely to manifest a delayed phase type disorder, which may present as difficulty falling asleep.

**Alcohol and Obstructive Sleep Apnea**

Alcohol use and AD have been associated with OSA in prior studies. Alcohol can impair normal breathing by impairing the normal arousal response to airway obstruction and by relaxing the upper airway musculature, leading to initiation or worsening of existing snoring, sleep-disordered breathing (SDB), and sleep fragmentation (Peppard et al., 2007; Sakurai et al., 2007; Vitiello, 1997).

In 1 study, subjects with AD in acute withdrawal demonstrated a higher intensity of respiratory events in their sleep (12.6 ± 12.3 events/h), as compared to healthy controls (3.6 ± 3.4 events/h) (Le Bon et al., 1997). In another study, a higher prevalence rate of SDB was seen in treatment-seeking patients with AD (41%), as compared to control subjects (23%). In this study, SDB was a significant contributor to sleep disturbance in a substantial proportion of male AD subjects above the age of 40 years (Aldrich et al., 1993). To the best of our knowledge, no data exists on the association of AD with central sleep apnea in the absence of other risk factors, such as comorbid congestive heart failure and opioid use.

**DISCUSSION**

A growing body of literature has demonstrated an association between AD and sleep-related disorders. The preponderance of this literature is on insomnia. Insomnia is being increasingly evaluated as a disorder of inappropriate arousal during sleep associated with involvement of multiple underlying mechanisms and downstream cognitive and behavioral manifestations. In addition, the role of circadian factors and sleep drive mechanisms in mediating and moderating insomnia are being recognized. The implications of this understanding have led to the use of behavioral interventions for its treatment and a role for newer medications such as ramelteon, which may also have the ability to advance circadian phase (Richardson et al., 2008). In addition, AD is being increasingly implicated with insufficient sleep duration, OSA, and PLMD.

One of the limitations associated with prior literature is the assessment of insomnia symptoms rather than insomnia as a disorder in people with AD. This may stem from the difficulty in distinguishing alcohol-induced insomnia from other causes of insomnia. Other limitations include small sample sizes, use of different assessment instruments across studies, lack of PSG to rule out other alcohol-associated sleep disorders, and heterogeneous samples with and without insomnia in PSG or treatment studies of recovering AD patients. Future studies should investigate the underlying mechanisms of insomnia in AD, the role of pharmacologic and behavioral treatments of insomnia using PSG, and the relationships of AD with other sleep disorders such as parasomnias.

**ACKNOWLEDGMENTS**

The study was supported by VA grant IK2CX000855 (SC). The content of this publication does not represent the views of the University of Pennsylvania, Department of Veterans Affairs, the United States Government, or any other institution. None of the authors report any actual or potential conflict of interests with this current manuscript.

**REFERENCES**

AASM (2014) International Classification of Sleep Disorders. 3rd ed. AASM, Darien, IL.


**SUPPORTING INFORMATION**

Additional Supporting Information may be found online in the supporting information tab for this article: Data S1. Search methodology.